Drug company won’t cut its $750-per-pill price; rival’s 99-cent version getting snatched up
After weeks of criticism from patients, doctors and even other drugmakers for hiking a life-saving medicine’s price more than fiftyfold, Turing Pharmaceuticals is reneging on its pledge to cut the $750-per-pill price.
After weeks of criticism from patients, doctors and even other drugmakers for hiking a life-saving medicine’s price more than fifty-fold, Turing Pharmaceuticals is reneging on its pledge to cut the $750-per-pill price.
Instead, the small biotech company says it’s reducing the price for hospitals by up to 50% for its Daraprim, which treats a rare parasitic infection that mainly strikes pregnant women and HIV patients.
The 62-year-old drug had no competition until a furor over the gigantic price hike erupted, triggering multiple government investigations.
Then a pharmacy that compounds prescription drugs for individual patients stepped in and started selling a capsule version for 99 cents. Imprimis Pharmaceuticals says orders are pouring in from doctors and it says it has dispensed more than 2,500 capsules in barely a month.
SIGN UP for the free California Inc. business newsletter >>
MORE FROM BUSINESS
New-home sales rebound in October
Average rate on 30-year mortgage slides to 3.95%
Stocks edge higher as trading winds down before Thanksgiving
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
